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The diagnosis and treatment of cancer continues to pose profound challenges. Over the past 50–60 years, significant advances 
have been made in the screening, early detection, 
diagnosis and treatment of cancer, resulting in 
the current cure rate of 40–60%.1–3 Together with 
surgery and radiotherapy, systemic chemotherapy 
has been the mainstay of cancer treatment for over 
half a century. However, conventional cytotoxic 
chemotherapy is fraught with both short- and long-
term side-effects, to the extent that many patients and 
caregivers consider the option of cancer treatment to 
represent a choice between ‘the devil and the deep sea’. 
Although combinations of cytotoxic chemotherapy are 
developed following rigorous evidence-based testing, 
a significant number of patients may not benefit from 
the combination and develop side-effects due to the 
non-selective nature of the treatment. Personalised 
and individualised treatment therefore remains a 
much desired but elusive goal for cancer patients, 
caregivers and healthcare professionals alike. 
Precision or personalised medicine aims to 
overcome the ‘one-size-fits-all’ approach to cancer 
care and tries to match the treatment with specific 
genotypic and/or phenotypic targets on the tumour 
so as to maximise efficacy and minimise side-effects.4 
Notably, the genetic profile of the cancer may change 
over time and hence this method of treatment also 
needs to be dynamic. Another important aspect of the 
personalised approach, beyond the individual tailoring 
of therapy, is the capacity to provide prognostic 
information. With gene-on-a-chip technology, the 
analysis of multiple biological determinants such as 
growth, metastatic potential and microenvironment 
regulators can be used to stratify tumour behavior. 
The seminal work by Perou et al. on the molecular 
characteristics of breast cancer opened the floodgates 
for genomic signature determinants to enable 
prognostication.5 
There are several dimensions of personalised 
medicine. First and foremost, it is important to ask 
ourselves whether, in the prevailing bio-psycho-
social model of health and illness, we can rely solely 
on genetic code to inform the choice of treatment, 
or if we also need to take into account other factors, 
such as environment and lifestyle, which have a very 
strong influence on overall health. Secondly, it may 
be prudent to distinguish between prognostic and 
predictive markers, although this may not always be 
possible. Whereas the intrinsic characteristics of the 
patient or disease are known as prognostic biomarkers 
which identify the likelihood of a clinical event, 
predictive biomarkers indicate whether a favourable 
or unfavourable effect would result from exposure to a 
certain therapeutic agent. While both of these aspects 
are important, for the purposes of this article, the focus 
of discussion will lie on predictive biomarkers which 
help not only in predicting the response to treatment, 
but also to tailor the treatment itself. 
So, what is our current understanding of an 
individual’s predictive biomarkers? In general, cancer 
denotes a heterogeneous group of diseases. Since 
the outcomes of treatment are overtly different in 
different patients, attempts have been made to classify 
and subclassify cancers based on either histological 
or biological characteristics and, more recently, 
molecular phenotype. As a result, some common 
cancers, such as breast cancer, colon cancer and 
non-Hodgkin’s lymphoma are no longer considered 
a single disease entity, but have been classified into 
several molecular types [Table 1].5–8 These molecular 
subtypes may provide either prognostic or predictive 
information, or both. A further refinement is that 
‘actionable’ predictive targets have been identified in 
many cancers, including non-small-cell lung cancer, 
Hodgkin’s lymphoma, melanomas and gastric, ureteral 
and uterine cancers [Table 2].9,10 For certain other 
cancers, molecular aberrations have become the sine 
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qua non for diagnosis, for example the breakpoint 
cluster region-Abelson murine leukaemia (BCR-ABL) 
translocation in chronic myeloid leukaemia and the 
c-kit mutation in gastrointestinal stromal tumours.11,12 
These are only a few examples, with the list of such 
cancers continuing to grow. These molecular targets 
not only guide treatment using targeted therapy, but 
may also help to determine the choice of conventional 
cytotoxic chemotherapy.
Therefore, it became possible to treat a subtype of 
tumour with a drug which has been specifically tailored 
to the tumour target. The first two drugs in this class of 
targeted therapy are monoclonal antibodies against the 
receptors expressed on the cell surface. Trastuzumab, 
a monoclonal antibody directed against epidermal 
growth factor receptor (EGFR)-2 or human epidermal 
growth factor receptor (HER)-2/neu, was found to 
improve progression-free survival in patients with 
breast cancer expressing the protein.13,14 Moreover, 
rituximab, a monoclonal antibody directed against the 
cluster of differentiation (CD)20 antigen expressed on 
activated B lymphocytes, was shown to improve both 
progression-free and overall survival in several types 
of B cell non-Hodgkin’s lymphoma.15,16 At almost the 
same time, a small-molecule tyrosine kinase inhibitor 
(TKI), later christened imatinib, was described; this 
agent inhibits phosphorylation at the adenosine 
triphosphate-binding site of the protein translated 
as a result of the BCR-ABL translocation in chronic 
myeloid leukaemia.11 The introduction of imatinib in 
2001 forever changed the landscape of treatment and 
outcomes for patients with chronic myeloid leukaemia 
as allogeneic bone marrow transplantations, with their 
attendant morbidity and significant mortality, were 
replaced by a tablet with very few, if any, significant 
side-effects and an equal degree of efficacy.17,18
These three drugs are regarded as the frontrunners 
of modern day precision medicine. Since then, a 
plethora of monoclonal antibodies and TKIs have been 
investigated, reported and approved for use in a variety 
of cancers and have resulted in improved response 
rates and progression-free and overall survival, in 
addition to reducing and, in some cases, alleviating 
toxicities associated with conventional cytotoxic 
chemotherapy.19 Nevertheless, although the side-effect 
profile of monoclonal antibodies and TKIs is different 
from that of conventional cytotoxic chemotherapy, 
it may sometimes be just as devastating. In addition 
to improving survival rates of common cancers, 
these medicines have also provided opportunities for 
therapy for individuals with otherwise difficult-to-
treat cancers.19 
However, challenges remain and treatment is 
often ‘hit or miss’, as not all patients with a certain 
target respond, or respond similarly, to a specific drug. 
For example, BRAF inhibitors produce remarkable 
responses in cases of metastatic malignant melanoma, 
but so far have not proved particularly effective 
in BRAF-mutant colon cancer.20 Some tumours 
continue to exhibit primary resistance to the specific 
molecularly-targeted drug and may even develop 
Table 1: Molecular subtypes of common cancer5–8
Type of cancer Molecular subtype




 ER/PgR-negative and HER-
2/neu-positive
Triple-negative 
Colon cancer Wild-type Ras
Mutant Ras 
Non-Hodgkin’s lymphoma B cell, CD19 and CD20
T cell and CD52 
Anaplastic large-cell and 
CD30
ER = estrogen receptor; PgR = progesterone receptor; HER = human 
epidermal growth factor receptor; CD = cluster of differentiation.
Table 2: Actionable targets and targeted therapy in 
selected cancers9,10
Type of cancer Target Treatment
Non-small-cell 
lung cancer




ROS1 fusion ROS1 TKI
Anaplastic large-
cell lymphoma







CD30 expression Anti-CD30 
antibody
Melanoma BRAF mutation BRAF inhibitors













EGFR = epidermal growth factor receptor; TKI = tyrosine kinase 
inhibitor; ALK = anaplastic lymphoma kinase; CD = cluster of 
differentiation; HER = human epidermal growth factor receptor; 
BRCA = breast cancer; PARP = polyadenosine diphosphate-ribose 
polymerase.
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secondary resistance during the course of treatment. 
There are several reasons for this; some cancers may 
have more than one pathway of oncogenesis and 
others, especially solid tumors, may not have one 
specific driver mutation leading to oncogenesis.20 These 
cancers may be dependent on tumour-environment 
interactions for progression. Furthermore, infiltration, 
invasion and metastasis remain the primary reason 
for dissemination in some cancers. Invariably, a 
metastatic tumour may harbor a different type of 
mutation and the elimination of one clone of cells may 
not be sufficient.20 
Nevertheless, the paradigm of cancer care 
is changing. Instead of classifying tumours by 
histological or biological behaviour, molecular targets 
are now being employed to classify tumors. Because 
of a common target, and the availability of tailored 
treatment for the target, different tumour types 
charcterised by the same molecular target respond 
similarly. For example, in addition to breast cancer, 
HER-2/neu is overexpressed in gastric, bladder 
and several other cancers and trastuzumab (the 
monoclonal antibody binding to the EGFR-2 receptor) 
has been shown to improve survival in cases of 
HER-2/neu overexpressing gastric cancer, although 
not to the same extent as in breast cancer.21 Similarly, 
patients with tumours with mutations in the breast 
cancer (BRCA) 1 and BRAC2 genes, such as high-
grade epithelial ovarian cancer, triple-negative breast 
cancer and prostate cancer, have exhibited prolonged 
progression-free survival when treated with the poly-
adenosine diphosphate-ribose polymerase inhibitor, 
olaparib, which induces a state of synthetic lethality.22 
Another example is microsatellite instability in mis-
match repair (MMR) genes. Data are beginning to 
emerge that MMR-deficient tumours may be more 
responsive to immunotherapy using anti-programmed 
cell death protein 1 (anti-PD1) antibodies, even if the 
mutation occurs in tumours as diverse as those seen in 
cancers of the colon, uterus, bladder or ureter.23 
Although molecular targets provide an oppor-
tunity for cancers to be treated with target-specific 
drugs, a significant number of tumours do not respond. 
Is personalised therapy therefore ‘illusive’ or ‘elusive’? It 
may be crucial to clearly distinguish between targeted 
therapy and precision medicine. On the one hand, 
targeted therapy is directed towards a molecular target 
in an individual, albeit one shared by a significant 
number of patients with a particular type of tumour or 
even across multiple types of tumours; therefore, it may 
be not be necessarily personalised in the true sense of 
the word. On the other hand, if personalised medicine 
needs to be precise enough to be individualised, then 
treatment such as chimeric antigen receptor T cell 
therapy may be an example. This first-of-its-kind drug 
was recently approved for the treatment of relapsed 
acute lymphoblastic leukaemia in children and young 
adults and has shown remarkable response and long-
term survival rates among patients whose disease 
relapsed after a bone marrow transplant.24 However, 
the drug is prohibitively expensive at the moment 
and may produce side-effects requiring transfer to the 
intensive care unit.
Also, there may be an economic dichotomy in 
the implementation of precision medicine. On the 
one hand, precision medicine is likely to identify 
susceptibility, preventative strategies, prognosis 
and appropriate targets for treatment, and hence 
may be cost-effective. As former USA President 
Barak Obama said in the mission statement for his 
precision medicine initiative: “It must enable a new 
era of medicine through research, technology, and 
policies that empower patients, researchers, and 
providers to work together toward the development 
of individualized care”.25 On the other hand, precision 
medicine initiatives require vast resources, such as 
the incorporation of extensive molecular profiling 
tests into clinical practice, which is clearly beyond the 
means of many healthcare programmes around the 
world, especially those in low- and middle-income 
countries.
In conclusion, the journey to personalised 
cancer treatment continues and, happily, this goal 
may no longer be quite so elusive. The advent of 
immunohistochemistry and monoclonal antibodies 
were torchbearers for tailored treatment. Gene 
sequencing, the identification of genetic mutations 
and the development of small-molecule TKIs have 
also allowed us to move away from the beaten path of 
cytotoxic chemotherapy.26 The identification of other 
targets such as proteasomes and cyclin-dependent 
kinases has also helped significantly in this regard. 
Other areas of research in precision medicine include 
the Cancer Genome Atlas, integrated proteogenomic 
analysis, next-generation sequencing, clustered regu- 
larly interspaced short palindromic repeat (CRISPR) 
mechanisms and translational research; these may 
result in designer drugs that pave the way for the near 
future.26 Nevertheless, while we seem to be moving in 
the right direction, we are still not past the winning 
post. Critically, all new drugs need to be validated 
in proper trials before they can be considered for 
clinical use, particularly as the detection of a target 
and the availability of a drug to hit that target does not 
guarantee clinically relevant efficacy.26 
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